- Previous Close
0.0200 - Open
0.0300 - Bid 0.0250 x --
- Ask 0.0300 x --
- Day's Range
0.0250 - 0.0300 - 52 Week Range
0.0150 - 0.1250 - Volume
33,400 - Avg. Volume
26,070 - Market Cap (intraday)
900,597 - Beta (5Y Monthly) 0.63
- PE Ratio (TTM)
-- - EPS (TTM)
-0.1000 - Earnings Date Apr 7, 2025 - Apr 11, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Restart Life Sciences Corp., through its subsidiaries, operates as a biotechnology company worldwide. It engages in developing diagnostics and psilocybin-based therapeutics for the treatment of neuroinflammatory disorders, including autism spectrum disorder and fragile X syndrome. The company was formerly known as Nova Mentis Life Science Corp. and changed its name to Restart Life Sciences Corp. in November 2024. Restart Life Sciences Corp. was incorporated in 2004 and is based in Vancouver, Canada.
www.restartlife.coRecent News: HEAL.CN
View MorePerformance Overview: HEAL.CN
Trailing total returns as of 1/16/2025, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: HEAL.CN
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: HEAL.CN
View MoreValuation Measures
Market Cap
720.48k
Enterprise Value
529.88k
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
20.56
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-895.11%
Return on Equity (ttm)
--
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-628.58k
Diluted EPS (ttm)
-0.1000
Balance Sheet and Cash Flow
Total Cash (mrq)
12.06k
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
170.14k